MRA convened its Fifth Annual Scientific Retreat in Washington, DC, February 27-28, 2013. The retreat brought together nearly 200 leading scientists and clinicians from around the world, as well as senior leadership from nonprofit foundations, corporate allies, government agencies, industry, and other key stakeholders to share early findings, identify future directions, discuss ideas, and look for synergies and partnerships. The retreat participants represented 50 academic institutions, 20 companies, and 7 countries.
The purpose of the retreat is to advance the melanoma field by facilitating early sharing of data in an interactive forum. The scientific sessions provided an opportunity for discussion of cutting-edge science focused on identifying new approaches to melanoma prevention and therapy. Highlights from this year's meeting included a welcome reception hosted by the Embassy of Australia and MRA's first-ever Industry Roundtable Breakfast. The roundtable breakfast facilitated a discussion among leaders in drug and device development, key academic opinion leaders, and government officials about opportunities and challenges for clinical progress in melanoma. Another highlight was the panel discussion focused on clinical care decision-making for today’s melanoma patients. Additionally, the retreat agenda featured special talks from Assistant Secretary for Health Howard Koh, FDA Commissioner Margaret Hamburg, and Director of the National Center for Advancing Translational Sciences Christopher Austin.
MRA is grateful to the following sponsors for their generous financial and in-kind support of the retreat, including: Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Eli Lilly, Pfizer Consumer Healthcare, Novartis, Daiichi Sankyo, Aduro Biotech, Amgen, Provectus Pharmaceuticals, Pfizer Oncology, National Pharmaceutical Council, Biotechnology Industry Organization, AdvaMedDx, Life Technologies, EntroGen, Vineyard Vines, Embassy of Australia, and Cynthia Hazen Polsky.